Insider · CIK 0001597583

Browne L Daniel

Reports to the SEC for 1 company · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001597583

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2019-06-28	Revance Therapeutics, Inc.J Other	Director, CEO and President	JOther	+1,000 sh	$11.02	+$11K	152,193
2019-03-18	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−11.6K sh	$15.51	−$180K	151,193
2019-03-15	Revance Therapeutics, Inc.F Tax Payment	Director, CEO and President	FTax Payment	−3,256 sh	$15.45	−$50.3K	165,687
2019-03-15	Revance Therapeutics, Inc.F Tax Payment	Director, CEO and President	FTax Payment	−2,881 sh	$15.45	−$44.5K	162,806
2019-02-19	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−5,446 sh	$17.68	−$96.3K	168,943
2019-02-15	Revance Therapeutics, Inc.F Tax Payment	Director, CEO and President	FTax Payment	−3,154 sh	$17.69	−$55.8K	174,389
2019-01-24	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, CEO and President	AAward	+200K sh	—	—	200,000
2019-01-24	Revance Therapeutics, Inc.A Award	Director, CEO and President	AAward	+35K sh	—	—	177,543
2018-06-29	Revance Therapeutics, Inc.J Other	Director, CEO and President	JOther	+668 sh	$23.33	+$15.6K	142,543
2018-03-16	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−5,452 sh	$31.43	−$171K	141,875
2018-03-16	Revance Therapeutics, Inc.M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	+20K sh	$2.55	+$51K	147,327
2018-03-16	Revance Therapeutics, Inc.Common StockM Exercise/Conversion	Director, CEO and President	MExercise/Conversion	+20K sh	—	—	0
2018-03-15	Revance Therapeutics, Inc.F Tax Payment	Director, CEO and President	FTax Payment	−2,881 sh	$31.65	−$91.2K	127,327
2018-03-15	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−1,000 sh	$32.80	−$32.8K	130,208
2018-03-07	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−27.3K sh	$31.43	−$858K	131,208
2018-02-15	Revance Therapeutics, Inc.F Tax Payment	Director, CEO and President	FTax Payment	−3,074 sh	$31.75	−$97.6K	158,491
2018-02-08	Revance Therapeutics, Inc.A Award	Director, CEO and President	AAward	+28.3K sh	—	—	161,565
2018-02-08	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, CEO and President	AAward	+169K sh	—	—	169,000
2017-12-29	Revance Therapeutics, Inc.J Other	Director, CEO and President	JOther	+127 sh	$22.99	+$2,920.048	133,315
2017-11-22	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−7,600 sh	$24.94	−$190K	133,188
2017-10-18	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−7,662 sh	$26.16	−$200K	140,788
2017-09-20	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−7,600 sh	$23.58	−$179K	148,450
2017-08-23	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−22.8K sh	$22.76	−$519K	156,050
2017-08-23	Revance Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	−331 sh	—	—	10,990
2017-08-23	Revance Therapeutics, Inc.M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	+331 sh	$2.55	+$844.05	178,850
2017-06-30	Revance Therapeutics, Inc.J Other	Director, CEO and President	JOther	+1,000 sh	$18.32	+$18.3K	178,519
2017-06-12	Revance Therapeutics, Inc.M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	+8,300 sh	$2.55	+$21.2K	177,519
2017-06-12	Revance Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	−8,300 sh	—	—	11,321
2017-05-30	Revance Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	−5,000 sh	—	—	19,621
2017-05-30	Revance Therapeutics, Inc.M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	+5,000 sh	$2.55	+$12.8K	169,219
2017-05-24	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−19.7K sh	$20.35	−$401K	164,219
2017-05-22	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−12.3K sh	$20.20	−$248K	183,932
2017-03-16	Revance Therapeutics, Inc.F Tax Payment	Director, CEO and President	FTax Payment	−3,171 sh	$19.20	−$60.9K	196,219
2017-02-22	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−1,269 sh	$20.70	−$26.3K	199,390
2017-02-22	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−9,768 sh	$20.56	−$201K	200,659
2017-01-26	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, CEO and President	AAward	+155K sh	—	—	155,000
2017-01-26	Revance Therapeutics, Inc.A Award	Director, CEO and President	AAward	+25.8K sh	—	—	210,427
2017-01-25	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−12K sh	$19.78	−$237K	184,627
2016-12-30	Revance Therapeutics, Inc.J Other	Director, CEO and President	JOther	+1,000 sh	$11.58	+$11.6K	196,627
2016-12-28	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−12K sh	$20.94	−$251K	195,627
2016-11-25	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−822 sh	$18.70	−$15.4K	207,627
2016-11-25	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−11.2K sh	$17.86	−$200K	208,449
2016-10-26	Revance Therapeutics, Inc.S Sale	Director, CEO and President	SSale	−12K sh	$14.85	−$178K	219,627
2016-05-19	Revance Therapeutics, Inc.F Tax Payment	Director, CEO and President	FTax Payment	−12.1K sh	$17.11	−$206K	231,627
2016-02-09	Revance Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, CEO and President	AAward	+175K sh	—	—	175,000
2016-02-09	Revance Therapeutics, Inc.A Award	Director, CEO and President	AAward	+25K sh	—	—	243,677
2015-12-31	Revance Therapeutics, Inc.J Other	Director, CEO and President	JOther	+262 sh	$27.00	+$7,074	218,677
2015-12-30	Revance Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	−12K sh	—	—	24,621
2015-12-30	Revance Therapeutics, Inc.M Exercise/Conversion	Director, CEO and President	MExercise/Conversion	+12K sh	$2.55	+$30.7K	218,415
2015-06-30	Revance Therapeutics, Inc.J Other	Director, CEO and President	JOther	+1,000 sh	$14.16	+$14.2K	1,000

Recent filings

Accepted (ET)
Jul 24
Browne L Daniel0001479290-19-000076
SEC(opens sec.gov)
Mar 194
Browne L Daniel0001479290-19-000038
SEC(opens sec.gov)
Feb 204
Browne L Daniel0001479290-19-000020
SEC(opens sec.gov)
Jan 254
Browne L Daniel0001479290-19-000018
SEC(opens sec.gov)
Jul 34
Browne L Daniel0001479290-18-000091
SEC(opens sec.gov)
Mar 164
Browne L Daniel0001479290-18-000050
SEC(opens sec.gov)
Mar 94
Browne L Daniel0001479290-18-000043
SEC(opens sec.gov)
Feb 164
Browne L Daniel0001479290-18-000025
SEC(opens sec.gov)
Feb 94
Browne L Daniel0001479290-18-000023
SEC(opens sec.gov)
Jan 34
Browne L Daniel0001479290-18-000002
SEC(opens sec.gov)
Nov 244
Browne L Daniel0001209191-17-062450
SEC(opens sec.gov)

Companies

Revance Therapeutics, Inc.Director, CEO and President

Address

C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD

NEWARK, CA, 94560